Ticking Off Investors, Akari CEO Exits Amid Coversin Trial Controversy

Akari, which is looking to ticks to provide a new PNH drug, has seen its CEO resign and investors launch class action suits amid controversy over a Phase II clinical trial for paroxysmal nocturnal hemoglobinuria.

Tick
Message From Investors To Akari: Don't Bite The Hand That Feeds You !! • Source: Shutterstock

More from Clinical Trials

More from R&D